RELEUKO is a Intravenous; Subcutaneous Injection, Solution in the Human Prescription Drug category. It is labeled and distributed by Amneal Pharmaceuticals Llc. The primary component is Filgrastim.
| Product ID | 70121-1568_0b7683ae-91e8-44b0-84a6-e185b84b5664 | 
| NDC | 70121-1568 | 
| Product Type | Human Prescription Drug | 
| Proprietary Name | RELEUKO | 
| Generic Name | Filgrastim | 
| Dosage Form | Injection, Solution | 
| Route of Administration | INTRAVENOUS; SUBCUTANEOUS | 
| Marketing Start Date | 2022-02-25 | 
| Marketing Category | BLA / | 
| Application Number | BLA761082 | 
| Labeler Name | Amneal Pharmaceuticals LLC | 
| Substance Name | FILGRASTIM | 
| Active Ingredient Strength | 300 ug/.5mL | 
| Pharm Classes | Granulocyte Colony-Stimulating Factor [CS], Granulocyte-Macrophage Colony-Stimulating Factor [CS], Increased Myeloid Cell Production [PE], Leukocyte Growth Factor [EPC] | 
| NDC Exclude Flag | N | 
| Listing Certified Through | 2023-12-31 | 
| Marketing Start Date | 2022-02-25 | 
| NDC Exclude Flag | N | 
| Sample Package? | N | 
| NDC | Brand Name | Generic Name | 
|---|---|---|
| 70121-1568 | RELEUKO | Filgrastim | 
| 70121-1569 | RELEUKO | Filgrastim | 
| 70121-1570 | RELEUKO | Filgrastim | 
| 70121-1571 | RELEUKO | Filgrastim | 
| 55513-209 | NEUPOGEN | Filgrastim | 
| 55513-530 | NEUPOGEN | Filgrastim | 
| 55513-546 | NEUPOGEN | Filgrastim | 
| 55513-924 | NEUPOGEN | Filgrastim | 
Mark Image Registration | Serial  | Company  Trademark Application Date  | 
|---|---|
![]() RELEUKO  90567963  not registered Live/Pending  | 
        KASHIV BIOSCIENCES, LLC  2021-03-09  | 
![]() RELEUKO  87594432  not registered Live/Pending  | 
        Adello Biologics, LLC  2017-09-01  |